We request an Agilent 6560C ion mobility mass spectrometer to accelerate our engineering biology platform. Industry globally is moving over to the use of bio-based and renewable sources for chemicals, such as plastics, detergents, dyes and medicines. Engineering biology is the term given to modifications of cells that can be our 'factories of the future'. It allows researchers to select or modify the ordinary chemical processes that the cells perform and provide them with new ones. In the case of mammalian cells such as the archetypical Chinese Hamster Ovary cells, synthetic biologists can produce extremely valuable protein medicines such as anti-cancer agents, vaccines and treatments for rare diseases. While our expert teams at UoE now have powerful automated systems for modifying mammalian cells, we struggle to test them to see how well they work and how good (and safe) the products are. Currently assessment of product quality is performed by simply measuring the yield of the products, and does not fully determine the structures or the modifications common to these proteins that can be responsible for safety and efficacy. Full product quality assessment must be done by multiple complex structural and chemical methods housed in multiple facilities. This means that we cannot optimise the engineering biology platform as well as we should be able to within the rapid turnaround times required by industry and modern academic research. The Agilent 6560C is an instrument that can characterise the product quality of high value proteins. With this system, we can 'close the loop' of engineering biology, and by using rapid testing, refine our engineered cells to make safer and better products. By adding this capability to EdinOmics and the portfolio of support facilities at the University of Edinburgh, we will provide world leading researchers into new medicines with the technology to take an idea for a new drug through early stage genetic engineering (via the Edinburgh Genome Foundry), through early stage production of a new medicine (via the Edinburgh Protein Production Facility) to testing of that medicine for quality (via this new instrument). Production of such highly polished early stage medicines can accelerate their uptake for clinical trials and hence medical use.